Literature DB >> 2430115

Age-related changes in tissue levels of prostatic acid phosphatase and prostate specific antigen.

D A Goldfarb, B S Stein, M Shamszadeh, R O Petersen.   

Abstract

Immunoperoxidase localization of prostatic tissue antigens has become useful in identifying the prostate as the origin of metastatic disease. Much research has been aimed at investigating the presence of these antigens in the adult prostate gland in benign and neoplastic states. Few studies have been done to determine the presence of these markers before puberty. We studied the prostate gland of 42 children of varying ages to determine the presence of these antigens at all age ranges to puberty. Sequential sections of the prostate were cut for prostate specific antigen, prostatic acid phosphatase, and hematoxylin and eosin staining. The degree of immunoperoxidase stain was graded from 0 to 4. The results showed that staining levels of prostate specific antigen and prostatic acid phosphatase were high at birth, decreased by age 6 months, reappeared by age 10 years and increased to puberty. Thus, the levels of prostate specific antigen and prostatic acid phosphatase appear to follow the testosterone levels, suggesting a hormonal dependence.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2430115     DOI: 10.1016/s0022-5347(17)45310-9

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  14 in total

1.  Aneuploidy of glandular epithelial cells in histologically normal prostate glands.

Authors:  T I Malinin; F J Hornicek; N L Block; G I Malinin
Journal:  Experientia       Date:  1988-03-15

Review 2.  Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies.

Authors:  Emma E van der Toom; Haley D Axelrod; Jean J de la Rosette; Theo M de Reijke; Kenneth J Pienta; Kenneth C Valkenburg
Journal:  Nat Rev Urol       Date:  2019-01       Impact factor: 14.432

3.  Prostatic acid phosphatase expression in human tissues.

Authors:  Thomas J Graddis; Catherine J McMahan; Jennifer Tamman; Keith J Page; James B Trager
Journal:  Int J Clin Exp Pathol       Date:  2011-03-22

4.  Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapy.

Authors:  C Wei; R A Willis; B R Tilton; R J Looney; E M Lord; R K Barth; J G Frelinger
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

Review 5.  mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer.

Authors:  Steffen Rausch; Christian Schwentner; Arnulf Stenzl; Jens Bedke
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

6.  Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies.

Authors:  Ravi A Madan; James L Gulley; Philip W Kantoff
Journal:  Cancer J       Date:  2013 Jan-Feb       Impact factor: 3.360

Review 7.  Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances.

Authors:  B Harpreet Singh; James L Gulley
Journal:  Ther Adv Vaccines       Date:  2014-09

Review 8.  Cellular prostatic acid phosphatase, a PTEN-functional homologue in prostate epithelia, functions as a prostate-specific tumor suppressor.

Authors:  Sakthivel Muniyan; Matthew A Ingersoll; Surinder K Batra; Ming-Fong Lin
Journal:  Biochim Biophys Acta       Date:  2014-04-18

Review 9.  Human prostatic acid phosphatase: structure, function and regulation.

Authors:  Sakthivel Muniyan; Nagendra K Chaturvedi; Jennifer G Dwyer; Chad A Lagrange; William G Chaney; Ming-Fong Lin
Journal:  Int J Mol Sci       Date:  2013-05-21       Impact factor: 5.923

Review 10.  Evolution of Cancer Vaccines-Challenges, Achievements, and Future Directions.

Authors:  Ban Qi Tay; Quentin Wright; Rahul Ladwa; Christopher Perry; Graham Leggatt; Fiona Simpson; James W Wells; Benedict J Panizza; Ian H Frazer; Jazmina L G Cruz
Journal:  Vaccines (Basel)       Date:  2021-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.